RxDoctor Payments Data

Martin Fejka, MD

Interventional Cardiology · Wheat Ridge, CONPI 1578521233

Payments from drug & device makers

$2,791in general payments, 2019–2025

Across 68 payments — averaging $41.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$1K
  • Abbott$295
  • Pfizer$251
  • Boston Scientific$246
  • Medtronic$245
  • Abiomed$182
  • plus $271 from 9 others

What the payments were for

  • Consulting fees$60021%
  • Food & beverage$2,17178%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,791 in reported general payments places this provider in the 25th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$252,415
Medicare patients
821
Services billed
2,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$241,185
XareltoRivaroxaban150$183,102
EntrestoSacubitril/Valsartan29$43,944
JardianceEmpagliflozin23$28,848
BrilintaTicagrelor16$11,056
Repatha SureclickEvolocumab18$10,222
Atorvastatin Calcium681$5,570
Rosuvastatin Calcium325$4,208
ClopidogrelClopidogrel Bisulfate326$3,949
Metoprolol Succinate418$3,877
Prazosin Hcl66$3,261
Nebivolol Hcl32$2,432
Lisinopril330$2,205
Losartan Potassium240$1,926
Spironolactone177$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$241,185214 claims
AstraZenecaBrilinta$14$11,05616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Wheat Ridge

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →